How is pseudomonas aeruginosa often transmitted

These antibiotics include methicillin and other more common antibiotics such as oxacillin, penicillin, and amoxicillin. In the community, most MRSA infections are skin infections.

More severe or potentially life-threatening MRSA infections occur most frequently among patients in Healthcare Settings.

Although anyone can get an NTM infection, NTM are opportunistic pathogens placing some groups at increased risk, including those with underlying lung disease or depressed immune systems. Gastroenteritis is an inflammation of the lining of the stomach and intestines, causing an acute onset of severe vomiting and diarrhea. Norovirus illness is usually brief in people who are otherwise healthy. Young children, the elderly, and people with other medical illnesses are most at risk for more severe or prolonged infection.

Like all viral infections, noroviruses are not affected by treatment with antibiotics. Pseudomonas infection is caused by strains of bacteria found widely in the environment; the most common type causing infections in humans is called Pseudomonas aeruginosa. Most of the time, staph does not cause any harm. These infections can look like pimples, boils, or other skin conditions and most are able to be treated. Transmission of Mycobacterium tuberculosis is a recognized risk to patients and healthcare personnel in healthcare facilities.

Transmission is most likely to occur from patients who have unrecognized pulmonary tuberculosis or tuberculosis related to their larynx, are not on effective anti-tuberculosis therapy, and have not been placed in tuberculosis isolation. Transmission of Mycobacterium tuberculosis in Healthcare Settings has been associated with close contact with persons who have infectious tuberculosis, particularly during the performance of cough-inducing procedures such as bronchoscopy and sputum induction.

Mycobacterium Tuberculosis is spread through air and can travel long distances. Persons who develop this type of staph infection may have underlying health conditions such as diabetes and kidney disease , devices going into their bodies such as catheters , previous infections with methicillin-resistant Staphylococcus aureus , and recent exposure to vancomycin and other antimicrobial agents.

Enteroccocci are bacteria that are normally present in the human intestines and in the female genital tract and are often found in the environment. These bacteria can sometimes cause infections. Most vancomycin-resistant Enterococci infections occur in hospitals. Skip directly to site content Skip directly to page options Skip directly to A-Z link. Healthcare-associated Infections. Section Navigation. Facebook Twitter LinkedIn Syndicate. Diseases and Organisms in Healthcare Settings.

Minus Related Pages. On this Page. Topical agents are frequently used to prevent infection of burn wounds, including silver sulfadiazine and mafenide Sulfanylon. Outbreaks of sulfadiazine-resistant organisms have occurred in burn units with its heavy usage. When topical agents are used prophylactically, there may be a delay in P. Mafemide has superior eschar penetration compared to silver sulfadiazine. Early and frequent debridement of necrotic tissue and excision of infected burn wounds is probably more important than topical therapy in preventing infection.

Bacteriophages have been tried see Adjunctive Therapy section. P atients with overt infection should be treated aggressively with combination IV antibiotics: an aminoglycoside and a beta-lactam. Antibiotic susceptibility testing is critical for antibiotic choice, since nosocomial strains may be multiply resistant. Patients with significant burns have dramatic alterations in pharmacokinetics of most drugs.

The risk in most patients may be under treatment rather than antibiotic toxicity The applicability of once daily dosing of aminoglycosides in burns patients is unknown, but is possibly advantageous.

Individualized pharmacokinetic dosing with monitoring of aminoglycoside serum concentrations is recommended. Prompt removal of infected intravenous catheters or other hardware such as a ventriculoperitoneal shunt or ear piercing, should be performed, whenever possible. In addition incision and drainage of abscesses, as well as debridement of soft tissue should be performed.

Debridement of the bony involvement in a puncture wound of the foot is necessary for resolution of the osteochondritis infection. Bacteriophages have been advocated as a potential topical application of treatment for post-burn P. A variety of phages are highly specific for P. A potential benefit of phage therapy is the lack of potential toxic effects, as well as diminished cost compared to systemic therapy.

Limited clinical studies have been performed on this approach to therapy 1 , with a clear need for further exploration of this therapy Bacteremia due to P. Risk factors for mortality include severe sepsis, pneumonia, and a delay in starting effective antimicrobial therapy. The choice and timing of antibiotic therapy is particularly crucial. As an example, in one study of episodes of P.

The prognosis of P. In a patient with primary or secondary bacteremia, blood cultures should become negative. For urinary tract infection, urine culture should become negative.

In a patient with P. The duration of therapy after an initial favorable clinical response is generally empiric. Bacteremia and urinary tract infections require at least 10 days of therapy. Meningitis should be treated for 21 days, and endocarditis for at least 42 days. T he goal for most therapy is a curative course of antibiotics for P. Demonstration of sterilization of cultures, resolution of pain, soft tissue swelling, and erythema are all clinical features to follow in patients with P.

In cystic fibrosis, a course of systemic antibiotics will reduce the bacterial burden of chronic infection with P. The endpoint for monitoring therapy of P. Persistent endotracheal colonization frequently occurs despite clinical response Currently, duration of therapy of days is suggested for P. However, if clinical criteria were used and ongoing colonization ignored , a duration of 8 days would appear reasonable Interest in a vaccine to prevent infection in susceptible hosts is tantalizing, especially in the care of patients with cystic fibrosis.

At present, no vaccine is commercially available, but development of vaccines against type II secretion system proteins, as well as LPS, is ongoing. In general P. The bacterium is a difficult organism to eradicate from areas that become contaminated, such as operating rooms, hospital rooms, clinics, and medical equipment.

In a hospital room occupied by a patient with a known infection from P. Bars of soap can become contaminated with P. Nosocomial spread of bacteria is frequently by hands, including P. Bacterial hand counts are higher with rings; long fingernails and artificial fingernails are associated with higher gram-negative bacterial hand contamination.

Education of hospital and all medical personnel on proper hand hygiene is vital for successful infection control of P. However, patient to patient transmission of multiply resistant P. In one investigation, three P. Molecular epidemiologic techniques i. A search for a common environmental source should be undertaken. Contact isolation precaution measures should be used as a mode of control of spread of such organisms if clonality is confirmed and no environmental source is found.

Such an approach requires the identification of asymptomatic carriers of the organism and then accommodation of such individuals in single rooms or cohorting with other colonized patients. Restriction of use of anti-Pseudomonal antibiotics should also be considered to reduce selective pressure leading to mutations contributing to multidrug resistance.

Cycling of antimicrobial agents used for empiric therapy has been attempted with some success in hospital intensive care units 6 , 94 , 95 , , , , , while more recent studies showed that cycling of antimicrobial agents did not control the emergence of gram-negative antimicrobial resistant organisms.

S team sterilization is the preferred method for preprocessing heat-stable medical devices. However manual cleaning to remove biological material is a necessary first step in reprocessing any medical device.

Disinfection and sterilization protocols do not work effectively on visibly soiled surfaces. The practice of rinsing equipment in tap water after preprocessing may contaminate a device. Patients with infections with P. Recommendations for good infection control practices for P.

Bacteriopharge therapy of Pseudomonas burn wound sepsis. Ann Medit Burn Club ; Pseudomonas aeruginosa flagella activate airway epithelial cells through asialoGM1 and toll-like receptor 2 as well as toll-like receptor 5.

Afessa B, Green B. Chest ; 4 Prolonged oral ciprofloxacin treatment of recalcitrant and severe osteomyelitis [Abstract ]. Ahmad SI. Treatment of post-burns bacterial infections by bacteriophages, specifically ubiquitous Pseudomonas spp. Med Hypotheses ;58 4 Impact of antibiotic changes in empirical therapy on antimicrobial resistance in intensive care unit-acquired infections.

J Hosp Infect ;52 2 Alvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. Intensive Care Med ;22 5 Delayed presentations of aortic valve endocarditis in patients with thermal injury.

J Trauma ;52 2 Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med ; 16 Microbes Infect ;5 12 Ball P. Emergent resistance to ciprofloxacin amongst Pseudomonas aeruginosa and Staphylococcus aureus: clinical significance and therapeutic approaches.

J Antimicrob Chemother ;26 Suppl F Baltch A, Smith R. Pseudomonas aeruginosa: infections and treatment. Otitis externa infection in Jordan. Clinical and microbiological features. Saudi Med J ;25 9 Development of beta-lactam resistance and increased quinolone MICs during therapy of experimental Pseudomonas aeruginosa endocarditis.

Antimicrob Agents Chemother ;32 2 Role of beta-lactamase in in vivo development of ceftazidime resistance in experimental Pseudomonas aeruginosa endocarditis. Antimicrob Agents Chemother ;31 2 Comparative study of combined cefepime-amikacin versus ceftazidime combined with amikacin in the treatment of nosocomial pneumonias in ventilated patients.

Multicenter group study]. Ann Fr Anesth Reanim ;18 2 Macrolides in cystic fibrosis. Chron Respir Dis ;2 2 Pseudomonas aeruginosa infections in the Intensive Care Unit: can the adequacy of empirical beta-lactam antibiotic therapy be improved? Int J Antimicrob Agents ;30 5 Pseudomonas aeruginosa tolerance to tobramycin, hydrogen peroxide and polymorphonuclear leukocytes is quorum-sensing dependent. Microbiology ; Pt 2 Bodmann KF.

Current guidelines for the treatment of severe pneumonia and sepsis. Chemotherapy ;51 5 An in vitro study of the potency and stability of fortified ophthalmic antibiotic preparations. Am J Ophthalmol ; 6 Boyce JM, Pittet D. Ophthalmic Pseudomonas infection in infancy. Arch Dis Child Fetal Neonatal. VAP Study Group. Clin Infect Dis ;26 2 In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.

J Antimicrob Chemother ;45 1 In vitro evaluation of the activity of two doses of Levofloxacin alone and in combination with other agents against Pseudomonas aeruginosa.

Diagn Microbiol Infect Dis ;46 2 Diagn Microbiol Infect Dis ;38 1 Microbiology of sputum from patients at cystic fibrosis centers in the United States.

Clin Infect Dis ;27 1 Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis ; 5 Canadian CCTG. A randomized trial of diagnostic techniques for ventilator-associated pneumonia. N Engl J Med ; 25 Meropenem administered as a prolonged infusion to treat serious gram-negative central nervous system infections. Pharmacotherapy ;24 6 Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents.

Antimicrob Agents Chemother ;43 6 Centers for Disease Control and Prevention. Infection Control Practices Advisory Committee. Pseudomonas aeruginosa infections associated with transrectal ultrasound-guided prostate biopsies--Georgia, Mixed infection in adult bacterial meningitis. Infection ;28 1 Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial.

Jama ; 19 Bacterial meningitis in hemodialyzed patients. J Nephrol ;17 2 Chmelik V, Gutvirth J. Meropenem treatment of post-traumatic meningitis due to Pseudomonas aeruginosa. J Antimicrob Chemother ;32 6 A double-blind, randomized, prospective trial of a topical antiseptic versus a topical antibiotic in the treatment of otorrhoea. Clin Otolaryngol Allied Sci ;15 1 Clinical and Laboratory Standards Institute. Seventh ed: Approved Standard; Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients.

Antimicrob Agents Chemother ;38 6 Committee on Infectious Diseases. The use of systemic fluoroquinolones. Pediatrics ; 3 Safety and tolerability of bolus intravenous colistin in acute respiratory exacerbations in adults with cystic fibrosis.

Ann Pharmacother ;34 11 Intrathecal amikacin for the treatment of pseudomonal meningitis. Ann Pharmacother ;38 6 Craig W, Ebert S. Antimicrobial therapy in Pseudomonas aeruginosa infections. Hot tub-associated necrotizing pneumonia due to Pseudomonas aeruginosa. Clin Infect Dis ;36 3 :e Ventilator-associated pneumonia due to Pseudomonas aeruginosa. Molecular epidemiology in a cluster of cases of postoperative Pseudomonas aeruginosa endophthalmitis.

Cystic Fibrosis Foundation. Seventh ed. Bethesda, MD: Approved Standard; Oral ciprofloxacin treatment of Pseudomonas aeruginosa osteomyelitis. Antimicrob Agents Chemother ;34 5 Adjuvant hyperbaric oxygen in malignant external otitis. Arch Otolaryngol Head Neck Surg ; 1 Evaluation of pefloxacin, ofloxacin and ciprofloxacin in the treatment of thirty-nine cases of chronic osteomyelitis.

Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection. J Clin Epidemiol ;48 8 Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother ;39 1 Etiology of severe pneumonia in the very elderly. Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates. Clin Infect Dis ;33 11 The comparison of in the vitro effect of imipenem or meropenem combined with ciprofloxacin or levofloxacin against multidrug-resistant Pseudomonas aeruginosa strains.

Int J Antimicrob Agents ;20 5 In vitro activity of combination therapy with cefepime, piperacillin-tazobactam, or meropenem with ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa strains. Chemotherapy ;49 6 Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother ;33 9 Mortality due to ventilator-associated pneumonia or colonization with Pseudomonas or Acinetobacter species: assessment by quantitative culture of samples obtained by a protected specimen brush.

Clin Infect Dis ;23 3 Is bronchoalveolar lavage with quantitative cultures a useful tool for diagnosing ventilator-associated pneumonia? Crit Care ;11 2 Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial. Ann Intern Med ; 8 Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections.

Clin Infect Dis ;40 9 Conditions for the emergence of resistance to cefpirome and ceftazidime in experimental endocarditis due to Pseudomonas aeruginosa. J Antimicrob Chemother ;33 3 Pseudomonas aeruginosa: growth in distilled water from hospitals.

Science ; Wei Sheng Wu Xue Bao ;40 2 Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin.

The Severe Pneumonia Study Group. Antimicrob Agents Chemother ;38 3 Aqueous and vitreous penetration of levofloxacin after oral administration.

Ophthalmology ; 12 FitzSimmons S. Meeting of the International B. Vigtoria, BC, Canada: ; Loss of bacterial diversity during antibiotic treatment of intubated patients colonized with Pseudomonas aeruginosa.

J Clin Microbiol ;45 6 Clin Infect Dis ;16 5 Pneumonia due to Pseudomonas aeruginosa: part I: epidemiology, clinical diagnosis, and source. Penetration of ceftazidime into the cerebrospinal fluid of patients with and without evidence of meningeal inflammation.

Antimicrob Agents Chemother ;26 1 In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin. J Antimicrob Chemother ;45 4 Antibacterial spectrum of a novel des-fluoro 6 quinolone, BMS Antimicrob Agents Chemother ;44 12 Chronic osteomyelitis caused by multi-resistant Gram-negative bacteria: evaluation of treatment with newer quinolones after prolonged follow-up. J Antimicrob Chemother ;39 2 Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines.

J Clin Microbiol ;39 1 Ciprofloxacin-resistant Pseudomonas keratitis. Ophthalmology ; 7 Left-sided endocarditis caused by Pseudomonas aeruginosa: successful treatment with meropenem and tobramycin. Diagn Microbiol Infect Dis ;47 2 Gerald B, Rhamphal R. Pseudomonas aeruginosa. Sixth ed. Philadelphia, PA: Elsevier; Immunomodulatory clarithromycin treatment of experimental sepsis and acute pyelonephritis caused by multidrug-resistant Pseudomonas aeruginosa.

Antimicrob Agents Chemother ;48 1 In vitro interaction of colistin and rifampin on multidrug-resistant Pseudomonas aeruginosa. J Chemother ;15 3 Giamarellou H. Malignant otitis externa: the therapeutic evolution of a lethal infection. J Antimicrob Chemother ;30 6 Antimicrob Agents Chemother ;19 5 Evaluation of combination chemotherapy in a lightly anesthetized animal model of Pseudomonas pneumonia.

Antimicrob Agents Chemother ;31 3 Gordon A, Isaacs D. Late onset neonatal Gram-negative bacillary infection in Australia and New Zealand: Pediatr Infect Dis J ;25 1 BMS formerly T, a des-fluoroquinolone potency and spectrum tested against over 10, bacterial bloodstream infection isolates from the SENTRY antimicrobial surveillance programme J Antimicrob Chemother ;49 5 Nosocomial endocarditis in the intensive care unit: an analysis of 22 cases.

Crit Care Med ;28 2 Synergistic activities of gatifloxacin in combination with other antimicrobial agents against Pseudomonas aeruginosa and related species. Antimicrob Agents Chemother ;45 11 Necrotizing malignant external otitis: prospective comparison of CT and MR imaging in diagnosis and follow-up.

Radiology ; 2 Greenberg JH. Green fingernails: a possible pathway of nosocomial pseudomonas infection. Mil Med ; 5 Rotation and restricted use of antibiotics in a medical intensive care unit. Impact on the incidence of ventilator-associated pneumonia caused by antibiotic-resistant gram-negative bacteria.

Strategy of antibiotic rotation: long-term effect on incidence and susceptibilities of Gram-negative bacilli responsible for ventilator-associated pneumonia.

Crit Care Med ;31 7 Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother ;47 3 Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in women: a nationwide analysis. Clin Infect Dis ;33 1 Human Toll-like receptor 4 recognizes host-specific LPS modifications.

Nat Immunol ;3 4 Risk factors for piperacillin-tazobactam-resistant Pseudomonas aeruginosa among hospitalized patients. Antimicrob Agents Chemother ;46 3 Pseudomonas aeruginosa community-acquired pneumonia in previously healthy adults: case report and review of the literature. Clin Infect Dis ;31 6 Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of patients. Am J Med ;87 5 Hoffken G, Niederman MS.

Nosocomial pneumonia: the importance of a de-escalating strategy for antibiotic treatment of pneumonia in the ICU. Chest ; 6 Holder IA. Pseudomonas immunotherapy: a historical overview. Vaccine ;22 7 Hooper D, Wolfson J. Mechanisms of bacterial resistance to quinolones. Washigton: American Society for Microbiology; Characterization of Pseudomonas aeruginosa isolates from patients with urinary tract infections during antibiotic therapy.

Microb Drug Resist ;9 2 The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest ; 1 Successful treatment of Pseudomonas ventriculitis with ciprofloxacin. J Antimicrob Chemother ;17 4 Use of magnetic resonance imaging as the primary imaging modality in the diagnosis and follow-up of malignant external otitis.

J Laryngol Otol ; 7 Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother ;42 11 Jackson G. Pseudomonas aeruginosa infection and treatment.

Pseudomonas bacteremia: pharmacologic and other bases for failure of treatment with gentamicin. J Infect Dis ; Suppl:S Pseudomonas osteochondritis complicating puncture wounds of the foot in children: a year evaluation. J Infect Dis ; 4 Emergence of ciprofloxacin-resistant pseudomonas in chronic suppurative otitis media.

Clin Otolaryngol Allied Sci ;29 4 Evaluation of topical povidone-iodine in chronic suppurative otitis media. Arch Otolaryngol Head Neck Surg ; 10 Failure of therapy in pseudomonas endocarditis: selection of resistant mutants. J Infect Dis ; 1 Johnson DE, Thompson B. Am J Med ;80 5C Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program Europe and the Americas; : more alike than different!

Diagn Microbiol Infect Dis ;41 3 Clarithromycin destroys biofilms and enhances bactericidal agents in the treatment of Pseudomonas aeruginosa osteomyelitis. Clin Orthop Relat Res Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis ;37 6 Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia.

Stable antimicrobial susceptibility rates for clinical isolates of Pseudomonas aeruginosa from the tracking resistance in the United States today surveillance studies. Clin Infect Dis ;40 Suppl 2:S Outbreak of Pseudomonas aeruginosa infections caused by commercial piercing of upper ear cartilage.

Jama ; 8 Survey of knowledge, beliefs, and practices of neonatal intensive care unit healthcare workers regarding nosocomial infections, central venous catheter care, and hand hygiene. Infect Control Hosp Epidemiol ;25 9 Susceptibility of corneal and conjunctival pathogens to ciprofloxacin. Cornea ;15 1 Scheduled change of antibiotic classes: a strategy to decrease the incidence of ventilator-associated pneumonia. Kollef MH, Ward S. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia.

Chest ; 2 Characteristics of left-sided endocarditis due to Pseudomonas aeruginosa in the Detroit Medical Center. Rev Infect Dis ;12 4 An in vitro resistance study of levofloxacin, ciprofloxacin, and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonas aeruginosa.

Ophthalmology ; 10 Gangrenous cellulitis associated with gram-negative bacilli in pancytopenic patients: dilemma with respect to effective therapy. Am J Med ;85 4 Pacemaker-related endocarditis. Report of 7 cases and review of the literature. Cardiology ;90 4 Siderophore-mediated signaling regulates virulence factor production in Pseudomonasaeruginosa.

Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned. Arch Intern Med ; 13 Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study.

Antimicrob Agents Chemother ;41 5 Selection of resistance by piperacillin during Pseudomonas aeruginosa endocarditis. J Antimicrob Chemother ;22 4 Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis ;28 5 In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis.

Pseudomonas aeruginosa infections are generally treated with antibiotics. Unfortunately, in people exposed to healthcare settings like hospitals or nursing homes, Pseudomonas aeruginosa infections are becoming more difficult to treat because of increasing antibiotic resistance.

To identify the best antibiotic to treat a specific infection, healthcare providers will send a specimen often called a culture to the laboratory and test any bacteria that grow against a set of antibiotics to determine which are active against the germ.

The provider will then select an antibiotic based on the activity of the antibiotic and other factors, like potential side effects or interactions with other drugs. For some multidrug-resistant types of Pseudomonas aeruginosa , treatment options might be limited. CDC tracks Pseudomonas aeruginosa and the infections this germ can cause, including antibiotic-resistant infections. Additionally, CDC works closely with partners, including public health departments, other federal agencies, healthcare providers, and patients, to prevent healthcare infections and to slow the spread of resistant germs.

Skip directly to site content Skip directly to page options Skip directly to A-Z link. Healthcare-associated Infections. Section Navigation. Facebook Twitter LinkedIn Syndicate. Pseudomonas aeruginosa in Healthcare Settings. Minus Related Pages.